NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome

Title
NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome
Authors
Keywords
Fragile X syndrome, Insulin growth factor 1, NNZ-2566, Behavior, Biomarkers
Journal
NEUROMOLECULAR MEDICINE
Volume 17, Issue 1, Pages 71-82
Publisher
Springer Nature
Online
2015-01-24
DOI
10.1007/s12017-015-8341-2

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started